About Us: Artera is an AI startup that develops medical artificial intelligence tests to personalize therapy for cancer patients. Artera is on a mission to personalize medical decisions for patients and physicians on a global scale.
The Artera Graduate Biostatistics Program invites Master's- and PhD-level statisticians to gain hands-on experience applying biostatistics in the AI healthcare industry. During the 3-month program, Biostatistics Associates will contribute to real product development, clinical evidence generation, and AI model validation projects while receiving structured mentorship and on-the-job training from Artera's Biostatistics team.
As a Biostatistics Research Associate at Artera, you will work at the intersection of biostatistics, oncology research, AI model development, and clinical evidence generation. You will work closely with biostatisticians, data analysts, machine learning scientists, clinical operations, medical affairs, regulatory, and product teams to support statistical analyses and data workflows for high-priority oncology programs.
This is a hands-on, project-based role working with real-world clinical datasets and contributing to analyses that support AI model development, clinical validation, regulatory submissions, publications, conference abstracts, collaborator updates, and internal decision-making.
Equal Employee Opportunity: At Artera, we value bringing together individuals from diverse backgrounds to develop new and innovative solutions for patients and physicians. As an equal opportunity employer, we do not discriminate on the basis of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information gender identity or expression, sexual orientation, marital status, protected veteran status, or any other legally protected characteristic.

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer.
Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.